RxDoctor Payments Data

Onala Telford, MD

Endocrinology, Diabetes & Metabolism · Annapolis, MDNPI 1497989685

Payments from drug & device makers

$1,877in general payments, 2019–2025

Across 94 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$529
  • Xeris Pharmaceuticals, Inc.$219
  • Lilly USA, LLC$193
  • Cequr Corporation$179
  • Dexcom, Inc.$149
  • Sanofi-aventis U.S. LLC$135
  • plus $472 from 13 others

What the payments were for

  • Food & beverage$1,86399%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,877 in reported general payments places this provider in the 50th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.

See all endocrinology, diabetes & metabolism providers in Maryland

Medicare billing

Part B allowed, 2024
$128,093
Medicare patients
365
Services billed
1,792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide161$346,553
MounjaroTirzepatide77$148,730
JardianceEmpagliflozin80$119,631
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/749$71,732
Fiasp FlextouchInsulin Aspart (Niacinamide)37$47,754
Tresiba Flextouch U-200Insulin Degludec31$40,327
RybelsusSemaglutide12$32,315
TrulicityDulaglutide17$30,281
FiaspInsulin Aspart (Niacinamide)27$27,008
FarxigaDapagliflozin Propanediol21$26,872
JanuviaSitagliptin Phosphate14$20,477
Tresiba Flextouch U-100Insulin Degludec27$14,858
Cequr SimplicityBolus Insulin Pump, 200 Unit15$14,506
Humalog Kwikpen U-100Insulin Lispro30$10,668
Nano 2nd Gen Pen NeedlePen Needle, Diabetic67$9,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Fiasp, Novolog$529$410,316214 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$193$182,320109 claims
AstraZenecaFarxiga$19$26,87221 claims
Cequr CorporationCequr Simplicity$179$14,50615 claims
AbbVieSynthroid$14$3,04030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.

Other endocrinology, diabetes & metabolism in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →